These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. Shea CM; Price GM; Liu G; Sarno R; Buys ES; Currie MG; Masferrer JL Am J Physiol Renal Physiol; 2020 Jan; 318(1):F148-F159. PubMed ID: 31608671 [TBL] [Abstract][Full Text] [Related]
24. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Boerrigter G; Burnett JC Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086 [TBL] [Abstract][Full Text] [Related]
25. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652 [TBL] [Abstract][Full Text] [Related]
26. Increased myocardial stiffness due to cardiac titin isoform switching in a mouse model of volume overload limits eccentric remodeling. Hutchinson KR; Saripalli C; Chung CS; Granzier H J Mol Cell Cardiol; 2015 Feb; 79():104-14. PubMed ID: 25450617 [TBL] [Abstract][Full Text] [Related]
27. Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease. Tobin JV; Zimmer DP; Shea C; Germano P; Bernier SG; Liu G; Long K; Miyashiro J; Ranganath S; Jacobson S; Tang K; Im GJ; Sheppeck J; Moore JD; Sykes K; Wakefield J; Sarno R; Banijamali AR; Profy AT; Milne GT; Currie MG; Masferrer JL J Pharmacol Exp Ther; 2018 Jun; 365(3):664-675. PubMed ID: 29643251 [TBL] [Abstract][Full Text] [Related]
28. Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1. Hopf AE; Andresen C; Kötter S; Isić M; Ulrich K; Sahin S; Bongardt S; Röll W; Drove F; Scheerer N; Vandekerckhove L; De Keulenaer GW; Hamdani N; Linke WA; Krüger M Circ Res; 2018 Jul; 123(3):342-355. PubMed ID: 29760016 [TBL] [Abstract][Full Text] [Related]
29. Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction. Methawasin M; Strom JG; Slater RE; Fernandez V; Saripalli C; Granzier H Circulation; 2016 Oct; 134(15):1085-1099. PubMed ID: 27630136 [TBL] [Abstract][Full Text] [Related]
30. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767 [TBL] [Abstract][Full Text] [Related]
31. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Hamdani N; Bishu KG; von Frieling-Salewsky M; Redfield MM; Linke WA Cardiovasc Res; 2013 Mar; 97(3):464-71. PubMed ID: 23213108 [TBL] [Abstract][Full Text] [Related]